362 related articles for article (PubMed ID: 12451478)
1. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
2. Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.
Papadopoulou MV; Bloomer WD; Taylor AP; Hernandez M; Blumenthal RD; Hollingshead MG
Radiat Res; 2007 Jul; 168(1):65-71. PubMed ID: 17722994
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
Papadopoulou MV; Ji M; Bloomer WD; Hollingshead MG
J Exp Ther Oncol; 2002; 2(5):298-305. PubMed ID: 12416033
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
Papadopoulou MV; Ji M; Ji X; Bloomer WD
Cancer Chemother Pharmacol; 2002 Oct; 50(4):291-8. PubMed ID: 12357303
[TBL] [Abstract][Full Text] [Related]
5. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
Papadopoulou MV; Bloomer WD; Hollingshead MG
Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
[TBL] [Abstract][Full Text] [Related]
6. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
Papadopoulou MV; Ji X; Bloomer WD
Anticancer Res; 2005; 25(3B):2161-70. PubMed ID: 16158959
[TBL] [Abstract][Full Text] [Related]
8. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
11. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2002; 13(1):47-54. PubMed ID: 12201674
[TBL] [Abstract][Full Text] [Related]
12. Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.
Papadopoulou MV; Bloomer WD; Torti VR; Page JG
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):497-504. PubMed ID: 20074267
[TBL] [Abstract][Full Text] [Related]
13. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
14. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
16. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
17. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
18. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
Siim BG; Menke DR; Dorie MJ; Brown JM
Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
[TBL] [Abstract][Full Text] [Related]
19. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
